How is biology disrupting life insurance?

0
453

Life insurance underwriting uses health, age, occupation, and other permitted information to estimate risk. Advances in genetics and epigenetics may improve medical understanding, but their use in insurance raises difficult questions about accuracy, consent, privacy, discrimination, and access to cover.

What genetics could mean for life insurance

Genetic information describes inherited variations in DNA. Epigenetics studies changes in gene activity that may be influenced by age, environment, and behaviour without altering the DNA sequence itself. Researchers are exploring whether these signals can improve health prediction.

A research finding does not automatically become a fair underwriting tool. Insurers need evidence that a measure is reliable, relevant to the covered risk, stable across populations, and useful beyond information already collected.

How life insurance underwriting works

Underwriters group applicants according to expected risk using information allowed by local law and company policy. The process may involve an application, medical history, examinations, laboratory results, and financial checks.

New data can affect pricing only if it improves risk classification in a defensible way. A model must also be explainable, monitored, and applied consistently. More data does not necessarily produce a better or fairer decision.

Potential uses of genetic and epigenetic data

  • Medical research: Improve understanding of disease pathways and longevity.
  • Risk assessment: Test whether new indicators add predictive value.
  • Prevention: Support health interventions when customers freely choose them.
  • Product design: Explore coverage and wellness services for changing health needs.

These uses should be separated carefully. Data collected for healthcare or research may not be appropriate for underwriting. Consent for one purpose does not automatically authorise another.

Accuracy and model risk

For life insurance decisions, many health outcomes result from interactions among genes, environment, behaviour, healthcare access, and chance. A genetic association may be statistically real but too weak for an individual prediction. Results may also perform differently across demographic groups.

Insurers must test calibration, error rates, bias, and stability. They should avoid deterministic language that treats a probability as a diagnosis. Independent review is important when a model could affect price or access.

Privacy, consent, and discrimination

Genomic information is highly sensitive and difficult to make anonymous. It can reveal information about biological relatives who never agreed to its collection. Security, retention, access control, and deletion policies therefore require special attention.

The World Health Organization’s genomic-data guidance emphasises ethical, legal, and equitable collection, access, use, and sharing. Insurers must follow the rules in each jurisdiction and explain any permitted use clearly.

How regulation differs by jurisdiction

Life insurance rules governing genetics are not universal. Some jurisdictions restrict or prohibit the use of predictive genetic tests. Others allow limited use under defined conditions or industry agreements.

For example, the UK Code on Genetic Testing and Insurance limits how insurers can request and use predictive test results. This example should not be treated as legal guidance for other countries.

Responsible innovation in life insurance

A responsible life insurance programme begins with a clear customer benefit and legal basis. It should use the least sensitive data needed, obtain meaningful consent where required, document model limitations, and provide human review and an appeal process.

Boards should oversee vendors, cybersecurity, data lineage, and fairness testing. The wider technology context is covered in FinTech Central’s InsurTech analysis and its discussion of the future of financial services.

What customers should understand

Life insurance customers should ask what information is required, why it is needed, how long it will be retained, who can access it, and whether the decision can be reviewed. They should also distinguish a clinical test from a consumer wellness or ancestry product.

Anyone making an insurance or health decision should consult the relevant insurer, regulator, and qualified professional. Rules and product terms vary by country and can change.

Conclusion

Genetics and epigenetics may contribute to medical knowledge and, in limited settings, insurance research. They are not simple replacements for established life insurance underwriting. Any use must meet demanding standards for evidence, legality, privacy, fairness, transparency, and customer protection.

FINTECH BRIEFING · A FUTURECENTRAL BRIEFING

Get practical financial AI analysis in your inbox.

Useful signals, focused analysis and decision questions on AI in banking, payments, lending, insurance, wealth and risk.

Free to subscribe. Confirm your email after signing up. Unsubscribe at any time.